Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report
Case Reports in Oncology · 04.08.2026 · 19 (1) · 1740-1746
DOI: 10.1159/000552719 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 04.08.2026. Verfasst von Morimi Fujita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Patients undergoing maintenance hemodialysis exhibit a unique immunological state characterized by chronic inflammation and T-cell dysfunction. Evidence regarding the efficacy and safety of combination chemoimmunotherapy in dialysis patients remains extremely limited. Case Report: We report a case of extensive-stage small cell lung cancer (performance status 1, cT1cN2M1c, stage IVB) in a patient undergoing maintenance hemodialysis who received 4 cycles of carboplatin (300 mg/m2, day 1), etoposide (50 mg/m2, days 1 and 3), and durvalumab (1,500 mg/body, day 1). Treatment was safely continued after adjusting the dosing schedule and dose levels in accordance with the dialysis schedule. Although new brain metastases developed during treatment and whole-brain radiotherapy was administered, computed tomography after 4 cycles demonstrated a partial response, and durvalumab maintenance therapy was subsequently continued. Grade 4 thrombocytopenia and grade 3 anemia and neutropenia were observed as adverse events; however, these were manageable with transfusion support and dose reduction. Disease progression was subsequently observed.
Conclusion
Carboplatin, etoposide, and durvalumab can provide meaningful therapeutic benefit even in patients undergoing maintenance hemodialysis when adverse events are appropriately managed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Medicine and Thoracic Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
- Clinical Research Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
- Department of Medical Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki City, Japan.
Zitieren
APA
Fujita, M., Matsunaga, N., Tsuji, H., Tamura, Y., Tsuruoka, K., Nakamura, T., Ikeda, S., & Fujisaka, Y. (2026). Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report. Case Reports in Oncology, 19(1), 1740-1746. https://doi.org/10.1159/000552719
Vancouver
Fujita M, Matsunaga N, Tsuji H, Tamura Y, Tsuruoka K, Nakamura T, et al. Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report. Case Reports in Oncology. 2026;19(1):1740-1746. doi:10.1159/000552719
BibTeX
@article{Fujita2026,
author = {Fujita, Morimi and Matsunaga, Ninso and Tsuji, Hiroyuki and Tamura, Yosuke and Tsuruoka, Kenjiro and Nakamura, Takahiko and Ikeda, Soichiro and Fujisaka, Yasuhito},
title = {Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1740--1746},
doi = {10.1159/000552719}
}
EUVIMED